Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose oral versus intravenous methylprednisolone for multiple sclerosis relapse
2007-000590-37Phase 3Active
- Sponsor
- CHU Rennes
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone in multiple sclerosis (MS) (2 arms), sponsored by CHU Rennes. Primary endpoint: Primary efficacy endpoint. Started May 2007; status: active.
02
Drugs
methylprednisolone
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2007-000590-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000590-37.